Imagine losing your vision for decades and then becoming able to detect objects again—with the help of light. This remarkable concept demonstrates the potential of optogenetics, the scientific field recognized by the 2026 Nobel Prize in Physiology or Medicine. In diseases such as retinitis pigmentosa, the retina’s light-sensitive photoreceptor cells progressively degenerate. However, some retinal neurons, including retinal ganglion cells, may remain functional. Optogenetic therapy offers an innovative strategy: instead of replacing lost photoreceptors, scientists can make surviving retinal cells responsive to light. In a landmark study, researchers delivered the gene encoding the light-sensitive protein ChrimsonR to retinal ganglion cells using an adeno-associated viral vector. Combined with specially engineered light-stimulating goggles, this approach enabled a patient with advanced retinitis pigmentosa to perceive, locate, touch, and even count certain objects. Importantly, this was not a complete restoration of normal vision, but a partial recovery of visual function and an important proof of concept for future therapies. The 2026 Nobel Prize in Physiology or Medicine was awarded to: 🔹 Karl Deisseroth – United States 🔹 Peter Hegemann – Germany 🔹 Georg Nagel – Germany Their discoveries helped establish optogenetics, allowing scientists to control selected nerve cells with light and transforming modern neuroscience. Al-Mustaqbal University – Ranked First Among Iraqi Private Universities